MIV-150 + LNG ring

Product Overview

Alternative Name: MZCL Combination IVR

Development Status: Inactive

Target: Female

Mode: Hormonal

Delivery Type: Vaginal Ring

Duration Type: Long-acting

Description: MIV-150 (an NNRTI that targets HIV) with zinc acetate (an antiviral agent with activity against HIV and HSV-2), carrageenan (an antiviral agent with activity against HPV) and levonorgestrel (LNG, a progestin) in an EVA or silicone vaginal ring.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): levonorgestrel, MIV-150, zinc acetate, carrageenan

Inactive material: EVA or Silicone

Potential Multi-Purpose Technology (MPT): Yes

Duration: 30 - 90 days

Dose: 10-70µg LNG (per day), MIV-150 ≥30µg; zinc acetate ≥100µg; carrageenan ≥500µg

Partner: Population Council, ProMed Pharma

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Status Details:
Prototype macaque MZCL IVRs have undergone preclinical testing. Funding for human MZCL IVR development is currently being pursued.

Programmatic Considerations

Considerations:
Need to demonstrate that MIV-150/zinc acetate/carrageenan and LNG do not interact adversely.

Additional Information

Additional Information:
Population Council Fact Sheet

Derby N, et al. (2017) An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv. and Transl. Res.

Download Product Report

Alternative Name: MZCL Combination IVR

Development Status: Inactive

Target: Female

Mode: Hormonal

Delivery Type: Vaginal Ring

Duration Type: Long-acting

Description: MIV-150 (an NNRTI that targets HIV) with zinc acetate (an antiviral agent with activity against HIV and HSV-2), carrageenan (an antiviral agent with activity against HPV) and levonorgestrel (LNG, a progestin) in an EVA or silicone vaginal ring.

Updated date: May 30, 2018

Vertical Tabs

Active Pharmaceutical Ingredient (API): levonorgestrel, MIV-150, zinc acetate, carrageenan

Inactive material: EVA or Silicone

Potential Multi-Purpose Technology (MPT): Yes

Duration: 30 - 90 days

Dose: 10-70µg LNG (per day), MIV-150 ≥30µg; zinc acetate ≥100µg; carrageenan ≥500µg

Partner: Population Council, ProMed Pharma

Project Phase: Early Development

Project Stage: Pre-clinical

Status Details: Prototype macaque MZCL IVRs have undergone preclinical testing. Funding for human MZCL IVR development is currently being pursued.

Considerations: Need to demonstrate that MIV-150/zinc acetate/carrageenan and LNG do not interact adversely.

Additional Information: Population Council Fact Sheet Derby N, et al. (2017) An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv. and Transl. Res.

Status Details:
Prototype macaque MZCL IVRs have undergone preclinical testing. Funding for human MZCL IVR development is currently being pursued.

Considerations:
Need to demonstrate that MIV-150/zinc acetate/carrageenan and LNG do not interact adversely.

Additional Information:
Population Council Fact Sheet

Derby N, et al. (2017) An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv. and Transl. Res.